FDA requesting more studies for Vertex's deuterated ivacaftor

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said FDA requested additional dose-finding studies, which could include monotherapy evaluation, of cystic fibrosis candidate VX-561 before the company brings it into late-stage development as part of a once-daily triple combination

Read the full 352 word article

User Sign In